Contributors
DM drafted the manuscript. AM conceived, and coordinated subsequent edits and revisions. MS and TR participated in drafting the manuscript and its finalization. All authors have read and approved the final manuscript.
Table 1 Disproportionality analysis (reporting odds ratio [ROR] and its 95% confidence interval [CI]) of selected cancers and total neoplasms for omalizumab in VigiBase for the period between 2000 and 2020.